Loading...
•
Dec 31, 2021
MindMed Q4 2021 Earnings Report
Reported full year financial results and business highlights.
Key Takeaways
MindMed reported its full year 2021 financial results, highlighting a cash balance of $133.5 million at year-end and advancements in its development programs. The company established a regulatory pathway for MM-120 in the treatment of GAD and for MM-402 launched a program to develop a treatment for autism spectrum disorder.
FDA cleared MindMed’s Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120
Progressed development programs for all three lead product candidates
Cash balance of $133.5 million at year end 2021
Robert Barrow was appointed as Chief Executive Officer and as a member of the Board of Directors
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...